AmerisourceBergen Corporation
ABCBusiness Model
source: coverage-next-full type: step_output step: 01 ticker: ABC company: Cencora, Inc. sector: Health Care generated: 2026-05-27
Step 01 — Business Overview: Cencora, Inc. (COR)
1. Company Summary
Cencora (formerly AmerisourceBergen) is the second-largest pharmaceutical distributor in the United States by revenue, and one of the largest healthcare services companies globally. Founded in 2001 from the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, the company rebranded to Cencora in August 2023 to better reflect its expanded, globally integrated identity [S1].
In FY2025 (fiscal year ended September 30, 2025), Cencora generated $321.3 billion in revenue, making it one of the largest companies in the world by revenue — roughly the GDP of a small-to-medium-sized nation. Yet its business is fundamentally one of logistics: moving pharmaceutical products through the supply chain as efficiently and reliably as possible, earning thin margins on massive volume.
The core business model: drug manufacturers produce medications and need to distribute them to the end points of care — pharmacies, hospitals, physician offices, clinics. Cencora sits as the intermediary, taking physical and economic ownership of drugs, warehousing them in temperature-controlled distribution centers, and delivering them rapidly and reliably. Manufacturers pay service fees (per-unit fees, data fees, logistics fees) and Cencora earns the spread between purchase price and sale price, with the spread driven largely by generic drug purchasing power and specialty distribution margins [S2].
2. Segment Structure
U.S. Healthcare Solutions (90.6% of FY2025 Revenue)
Revenue: $291.0B (FY2025), +9.7% YoY
The U.S. segment is divided into:
U.S. Human Health ($285.3B, +9.7%):
- Traditional pharmaceutical distribution to retail pharmacies (Walgreens is the largest customer), health systems, clinics, and specialty physician practices
- Specialty distribution (AmerisourceBergen Specialty Group / ABSG): Oncology, retina (post-RCA acquisition January 2025), neurology, rheumatology, dermatology — drugs dispensed directly in physician offices
- Manufacturer services: Clinical trial support, commercialization support, packaging, pharmacy management
- GLP-1 products: Became a dominant driver; +26.9% growth (+$7.7B) in FY2025 [S1]
- OneOncology (acquired February 2026): ~500+ physician practices, community oncology platform; adds further specialty depth
U.S. Animal Health ($5.7B, +6.1%):
- MWI Veterinary Supply: Distributes pharmaceuticals and products to companion animal and production animal markets
- Now classified as "Other" starting FY2026 as management explores strategic alternatives
Retina Consultants of America (RCA):
- Acquired January 2025 for ~$3.9B cash; ~85% Cencora ownership
- 200+ affiliated retina practices; largest retinal specialty practice network in U.S.
- Added significantly to FY2025 gross profit (+23% U.S. GP, driven by RCA)
- Classified within U.S. Human Health
International Healthcare Solutions (9.4% of FY2025 Revenue)
Revenue: $30.4B (FY2025), +6.1% YoY
Alliance Healthcare ($24.4B, +5.8%):
- Pan-European pharmaceutical distributor; acquired 2021 for ~$6.5B
- Operations in UK, Spain, Germany, Portugal, Turkey, and other European markets
- Standard pharmaceutical distribution with some retail pharmacy network
- Higher GP margin (~10-11%) than U.S. distribution business
Other International Healthcare Solutions ($6.0B, +7.3%):
- World Courier: Global specialty pharmaceutical logistics for clinical trials and biopharma
- PharmaLex: Regulatory affairs, pharmacovigilance, development consulting for life sciences (acquired January 2023; $1.4B; now subject to goodwill impairments — $418M FY2024, $724M FY2025)
- Innomar Strategies (Canada): Specialty pharmaceutical services
- Profarma (Brazil): Full-line pharmaceutical distribution (less-than-wholly-owned)
3. Value-Chain Position
MANUFACTURER → [Cencora] → HEALTHCARE PROVIDER → PATIENT
↓
Distribution Centers (~30 in U.S.)
Temperature-controlled warehousing
Track-and-trace serialization
Credit and payment terms management
Returns management
Cencora sits between ~1,500+ pharmaceutical manufacturers and ~100,000+ healthcare provider customers. This intermediary position generates several types of economic value:
- Logistics efficiency: Manufacturers need not maintain direct-to-provider networks; Cencora's scale is irreplaceable
- Working capital intermediary: Cencora extends credit to pharmacies and health systems, funded by supplier payment terms from manufacturers; the difference in DPO (60 days) vs. DSO (28 days) creates working capital float
- Data and analytics: Purchase data from across the supply chain is monetized via manufacturer consulting and analytics services
- Specialty access: In specialty segments, Cencora provides REMS program support, reimbursement services, and patient adherence tools that manufacturers cannot easily replicate
4. Revenue Model
| Revenue Type | Estimated % of Revenue | Margin Profile |
|---|---|---|
| Brand pharmaceutical distribution | ~60-65% | Very thin (~1-2% GP margin) |
| Generic pharmaceutical distribution | ~15-20% | Higher (~4-6% GP margin) |
| Specialty pharmaceutical distribution | ~8-12% | Best (~5-8% GP margin) |
| RCA / physician services | ~2-3% | High (~40%+ service margin) |
| International (Alliance Healthcare) | ~7-8% | Medium (~10-11% GP margin) |
| Other (World Courier, PharmaLex, etc.) | ~2-3% | Variable |
5. Customer Concentration
- Top 2 customers represent ~37% + ~5% of accounts receivable (per FY2024 10-K) [S2]
- Walgreens Boots Alliance (WBA) is widely understood to be the largest customer
- Second-largest is likely Express Scripts / Evernorth (Cigna subsidiary); supply agreement extended through September 2029
- Healthcare system customers (hospital groups, IDNs) represent a growing and diversifying base
- GLP-1 pharmacy concentration: Significant sales to WBA and mail-order customers
6. Key Business Metrics (FY2025)
| KPI | Value |
|---|---|
| Revenue | $321.3B |
| Gross Profit | $11.5B (3.57% margin) |
| U.S. Healthcare Solutions Operating Income | $3.57B (1.23% margin) |
| International Operating Income | $648M (~2.1% margin) |
| Operating Cash Flow | $3.9B |
| Free Cash Flow (est.) | ~$3.2B |
| Days Sales Outstanding (DSO) | 27.9 days |
| Days Inventory on Hand (DIOH) | 27.0 days |
| Days Payable Outstanding (DPO) | 59.6 days |
| Shares Outstanding | ~190M (est.) |
Source Index
| ID | Source |
|---|---|
| S1 | Cencora FY2025 10-K (Sep 30, 2025), EDGAR |
| S2 | Cencora FY2024 10-K (Sep 30, 2024), EDGAR |
| S3 | Cencora Q2 FY2026 10-Q (Mar 31, 2026), EDGAR |
Financial Snapshot
source: coverage-next-full type: step_output step: 04 ticker: ABC company: Cencora, Inc. sector: Health Care generated: 2026-05-27
Step 04 — Financial Snapshot & Quality: Cencora, Inc. (COR)
1. Income Statement Analysis (5-Year)
Revenue & Profitability ($ millions, except per-share)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $213,989 | $238,587 | $262,173 | $293,959 | $321,333 |
| YoY Growth | — | +11.5% | +9.9% | +12.1% | +9.3% |
| Gross Profit | ~$9,316 | $8,296 | $8,959 | $9,910 | $11,479 |
| Gross Margin | ~4.4% | 3.5% | 3.4% | 3.4% | 3.6% |
| Segment Operating Income | — | ~$2,925 | $3,289 | $3,648 | $4,223 |
| GAAP Operating Income | — | $1,908 | $2,341 | $2,175 | $2,629 |
| GAAP Net Income | ~$1,703 | ~$1,700 | ~$1,716 | ~$1,503 | ~$1,517 |
| Adj. EPS (Diluted) | ~$10.00 | ~$10.50 | ~$12.00 | ~$13.50 | ~$15.50 [est.] |
| GAAP EPS (Diluted) | ~$8.18 | ~$8.35 | ~$8.74 | ~$7.76 | ~$8.50 [est.] |
Note: FY2024 GAAP EPS suppressed by $418M goodwill impairment; FY2025 by $724M impairment. FY2025 adjusted EPS guidance: $17.65-$17.90 per company guidance (FY2026 raising implies FY2025 actual was in that range pre-raise).
Statement Quality Adjustments
1. LIFO Inventory Accounting: Cencora uses LIFO (last-in, first-out) for its U.S. pharmaceutical inventory. When drug prices inflate, LIFO creates an expense (LIFO expense) that reduces reported gross profit. When prices deflate (as in FY2024-FY2025 due to generic deflation and brand price decreases), LIFO creates a credit:
- FY2023: LIFO expense ($204.6M) — reduced gross profit
- FY2024: LIFO credit $52.2M — added to gross profit
- FY2025: LIFO credit $76.9M — added to gross profit
Adjustment: To compare periods, add back LIFO expense or subtract LIFO credit.
2. Antitrust Litigation Settlement Gains: Recurring gains from pharmaceutical manufacturer antitrust settlements (recorded as COGS reduction):
- FY2023: $239.1M
- FY2024: $170.9M
- FY2025: $236.4M
Adjustment: These are recurring but irregular; should be treated as below-the-line items.
3. Goodwill Impairments (PharmaLex):
- FY2024: $418M goodwill impairment (PharmaLex)
- FY2025: $724M goodwill impairment (PharmaLex + equity investment impairment $113.5M)
Adjustment: Remove from operating income; these reflect acquisition overpayment, not operating performance.
4. Opioid Litigation:
- FY2023: $24.7M credit (received H.D. Smith escrow)
- FY2024: $227.1M expense
- FY2025: $60.7M credit
Adjustment: Non-recurring in nature; exclude from adjusted earnings.
5. Turkey Hyperinflation:
- FY2023: ($87.0M) expense
- FY2024: ($54.1M) expense
- FY2025: ($49.6M) expense
Ongoing due to Turkish Lira devaluation; reflects the risk of Alliance Healthcare's Turkey operations.
6. Acquisition-Related Charges:
- FY2025: $291M deal & integration + $229M restructuring
- These are large and recurring as Cencora integrates Alliance Healthcare, PharmaLex, RCA, and OneOncology
Net Effect of Adjustments on Operating Income: When removing impairments, litigation, and other non-recurring items, "adjusted" segment operating income of $4.22B in FY2025 (vs. $2.63B GAAP) better represents underlying earning power.
2. Balance Sheet Analysis
Simplified Balance Sheet (September 30 estimates)
| Item | FY2022 est. | FY2023 est. | FY2024 est. | FY2025 est. |
|---|---|---|---|---|
| Cash & Equivalents | ~$2,200M | ~$2,600M | ~$3,100M | ~$4,000M |
| Accounts Receivable | ~$17,000M | ~$19,500M | ~$22,300M | ~$24,000M |
| Inventories | ~$17,000M | ~$19,000M | ~$20,500M | ~$22,000M |
| Total Current Assets | ~$40,000M | ~$44,000M | ~$48,000M | ~$53,000M |
| Goodwill + Intangibles | ~$14,000M | ~$16,000M | ~$15,000M | ~$20,000M [post-RCA] |
| Total Assets | ~$50,000M | ~$56,000M | ~$60,000M | ~$80,000M [post-RCA+OneOnc] |
| Accounts Payable | ~$36,000M | ~$42,000M | ~$47,000M | ~$51,000M |
| Long-Term Debt | ~$5,500M | ~$6,500M | ~$7,000M | ~$14,000M [post-RCA debt] |
| Stockholders' Equity | ~$2,800M | ~$3,100M | ~$3,200M | ~$3,000M |
Note: Balance sheet estimates are based on XBRL data plus filing text. Significant debt increase in FY2025 due to $1.8B senior notes + $1.5B term loan for RCA; further increase Q2 FY2026 for OneOncology ($4.6B+ new financing).
Key observation: Cencora runs with near-negative equity when goodwill is stripped out (net tangible equity is negative). This is a feature of capital-light, high-velocity distribution businesses with massive trade payable leverage — NOT a sign of insolvency. The company's true capital position is reflected in its free cash flow generation.
3. Cash Flow Quality
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $3,900M | $3,500M | $3,900M |
| Capital Expenditures | $458M | $487M | $668M |
| Free Cash Flow | $3,442M | $3,013M | $3,232M |
| FCF / Net Income | ~2.0x | ~2.0x | ~2.1x |
| FCF / Adjusted Operating Income | ~79% | ~83% | ~77% |
| Capex / Revenue | 0.17% | 0.17% | 0.21% |
Cash flow quality assessment: HIGH
- OCF consistently exceeds reported net income (2x+ coverage) due to non-cash charges (D&A, impairments) and working capital mechanics
- Very capital-light in the distribution business (CapEx is 0.2% of revenue — nearly negligible)
- FY2025 FCF of $3.2B funds dividends ($437M), buybacks ($436M), and still contributes to debt reduction/M&A funding
- Guidance for FY2026 CapEx = $900M (significant increase for network expansion + OneOncology integration)
4. Adversarial Research Sweep
4a. Opioid Litigation
Summary: Cencora was a central participant in the U.S. opioid epidemic litigation. As a major distributor of opioid medications, the company is alleged to have prioritized profit over flagging suspicious orders.
Settlement details:
- National settlement (joint with MCK and CAH): ~$21B over 18 years; Cencora's share approximately $6.1B over 18 years
- FY2025: Still 13 more years of opioid payments remaining
- Annual opioid payment run rate: ~$400-500M
- Director settlement: $111M separate settlement with shareholders alleging board oversight failure
- FY2025 litigation line: $60.7M net credit (timing of payments/settlements)
Risk assessment: Material but contained. The settlement is structured; Cencora's cash flows ($3.2B FCF) comfortably cover annual payments. The primary risk is additional litigation from remaining plaintiffs not covered by the national settlement.
4b. PharmaLex Acquisition Quality
Issue: Cencora acquired PharmaLex (regulatory consulting) in January 2023 for $1.4B. Within 18 months, it recorded $418M goodwill impairment (FY2024) and $724M impairment (FY2025) — together exceeding the acquisition price.
Analysis: This represents a clear acquisition failure. Management overpaid significantly for PharmaLex. The company is now exploring strategic alternatives for the consulting services businesses. This raises questions about M&A discipline, though it is worth noting that Alliance Healthcare (much larger acquisition) has performed well.
4c. Cybersecurity Incident (March 2024)
Issue: In March 2024, Cencora experienced a cybersecurity event where data was exfiltrated from its information systems. The incident was disclosed in the FY2024 10-K.
Impact: Costs recorded in "Other, net" within restructuring; amount not separately quantified but described as "majority of Other, net costs in FY2024." Likely a few tens of millions of dollars in remediation.
Risk: Ongoing. Cencora handles sensitive patient and pharmaceutical data; the 2024 breach increases the scrutiny of its cybersecurity posture. A follow-on incident could be more costly.
4d. WBA Customer Concentration Risk
Issue: Walgreens Boots Alliance (WBA) is Cencora's largest customer. WBA has been facing serious financial difficulties — pharmacy reimbursement rate pressure, retail store losses, and ongoing restructuring. WBA has been closing stores and may reduce purchasing volumes.
Impact: WBA represents ~37% of Cencora's top-2 accounts receivable. Any significant reduction in WBA purchases would be material to Cencora's revenue.
Mitigating factors: Long-term supply agreement through 2029; Cencora cannot easily be replaced as WBA's distributor; WBA has contracted to purchase minimums.
4e. OneOncology Acquisition Risk (Feb 2026)
Issue: Cencora acquired the remaining ~92% of OneOncology in February 2026 for ~$4.6B cash + $752M contingent consideration + assumed equity. Total fair value ~$7.4B. This is on top of RCA ($3.9B, Jan 2025). Combined, these two deals added ~$8B+ of cash outflow in 13 months, funded largely by new debt.
Analysis: The speed and scale of M&A is aggressive. PharmaLex failure is precedent for risk. However, OneOncology's community oncology model has a clearer strategic rationale — it directly drives specialty pharmaceutical volume at independent oncology practices that are Cencora's natural distribution customers. The key risk is integration execution and debt service burden.
5. Financial Quality Summary
| Dimension | Assessment | Score (1-5) |
|---|---|---|
| Revenue quality | Highly visible; contract-based; diversified customer base | 4 |
| Earnings quality | Non-GAAP >> GAAP due to impairments; cash earnings are real | 3-4 |
| Cash flow quality | FCF consistently >2x net income; minimal CapEx | 5 |
| Balance sheet | Negative tangible equity; high goodwill; but manageable | 3 |
| Governance quality | Opioid oversight failures; PharmaLex error; but improving | 3 |
| M&A track record | Alliance Healthcare (success); PharmaLex (failure); RCA/OneOncology (TBD) | 3 |
Overall Financial Quality: MODERATE-HIGH (3.5/5)
Cash flow generation is excellent; the balance sheet is structurally leveraged (by design for a distribution company); GAAP earnings are heavily distorted by recurring non-cash items. Investors must focus on adjusted earnings and FCF.
Source Index
| ID | Source |
|---|---|
| S1 | Cencora FY2025 10-K, EDGAR |
| S2 | Cencora FY2024 10-K, EDGAR |
| S3 | SEC XBRL, EDGAR |
| S4 | Tavily search — opioid settlement, cybersecurity |
Recent Catalysts
source: coverage-next-full type: step_output step: 12 ticker: ABC company: Cencora, Inc. sector: Health Care generated: 2026-05-27
Step 12 — Bull/Bear: Cencora, Inc. (COR)
Note on Methodology: This step was produced using the filings-and-consensus path (coverage-next-full). Earnings transcripts were not loaded; the bull/bear debate is inferred from consensus analyst commentary, MD&A language, press releases, and Tavily research. The analyst debate structure follows the Step 12 framework as adapted for the filings-only path.
Current Situation (May 2026)
Cencora (COR) is trading at ~$265/share, down 27% from its 52-week highs ($370-400) recorded in early 2026 before the Q2 FY2026 results (May 6, 2026). The Q2 FY2026 results were a mixed quarter: adjusted EPS beat ($4.75 vs. $4.73), but revenue fell slightly short and management cited customer losses (oncology, grocery) and GLP-1 growth deceleration. Multiple analyst price target cuts followed (Evercore: $300-$360→$300; Citi: $355-$405→$355), but Barclays reiterated Buy and UBS raised its target to $412 [S5].
The company trades at ~15x FY2026E adjusted EPS of $17.65-$17.90 guidance. Consensus implies 29.8% upside from current levels [S5].
Bull Case
Bull Thesis Statement: Cencora is a durable oligopolist executing a strategically sound expansion into high-margin specialty physician services (RCA retina + OneOncology) that will compound adjusted EPS at 8-12% annually for the next 5 years, with the stock's current discount to fair value (~30%) representing a compelling entry for long-duration capital.
Bull Bullet 1: Specialty Expansion Directly Addresses the Margin Ceiling The historical knock on pharmaceutical distributors is that gross margins are structurally capped at 2-3.5% (thin logistics economics). Cencora's RCA and OneOncology acquisitions directly attack this ceiling by embedding within physician practices that buy-and-bill specialty drugs at 30-50% gross margins. In just FY2025, RCA alone drove U.S. Healthcare Solutions GP margin to 2.72% (+30 bps) and U.S. segment operating income to $3.57B (+21.8%). OneOncology adds a much larger specialty network (~500+ physicians) that will further expand margins as it integrates. At maturity, Cencora could sustain 3-4% consolidated GP margins vs. the 2.4% it was earning in FY2022 [S1].
Bull Bullet 2: GLP-1 Secular Tailwind Has Years of Runway GLP-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound) are generating the pharmaceutical industry's largest-ever product cycles. Cencora grew GLP-1 revenue by $8.6B (+43%) in FY2024 and $7.7B (+27%) in FY2025. While H1 FY2026 growth has slowed to +16-23%, the absolute dollar growth (~$2B in a single quarter) remains massive. IQVIA forecasts the U.S. pharmaceutical market to grow at 8.2% CAGR through 2028, with GLP-1 as a primary driver. As GLP-1 indications expand (obesity, cardiovascular, CKD, sleep apnea), the total addressable market grows beyond the ~$45B current estimated annual run rate. Cencora is the distribution infrastructure for this secular trend [S1].
Bull Bullet 3: $265 Represents a Historically Discounted Multiple on Durable Earnings Power At $265, COR trades at ~15x FY2026E adjusted EPS of $17.75 midpoint. The five-year adjusted EPS CAGR has been ~15%+ (from ~$10 in FY2021 to $17.75E in FY2026). Consensus expects ~$19.77 in FY2027E EPS (+11% growth), implying a forward P/E of only ~13x — historically cheap for a business with 20%+ ROIC on invested capital, durable oligopolistic position, and expanding specialty margins. Historical 5-year average P/E for COR has been ~18-22x. If multiples simply normalize to 17-18x on $19.77 FY2027 EPS, the stock is worth $336-$356, representing 26-34% upside [S5, S6].
Bear Case
Bear Thesis Statement: Cencora is an oligopolistic distributor that has over-leveraged its balance sheet (~$18B net debt) through a string of expensive acquisitions (PharmaLex failed; RCA and OneOncology's ROICs are uncertain), while its core U.S. revenue growth decelerates to 3-4% as GLP-1 growth normalizes, customer losses compound, and WBA's financial fragility threatens the single largest customer relationship.
Bear Bullet 1: The M&A Treadmill Is Destroying Capital Cencora has deployed ~$11B+ of capital in 13 months (RCA $3.9B + OneOncology $7.4B FV), on top of the $1.4B PharmaLex write-off. PharmaLex — acquired for $1.4B, impaired by $1.14B in just 2 years — shows the management team can overpay significantly for professional services acquisitions. OneOncology was purchased at $7.4B fair value for a community oncology network. If OneOncology follows PharmaLex's trajectory (integration difficulties, consulting/professional services harder to manage than distribution), another multi-billion goodwill impairment cycle could be ahead. Combined impairments over FY2024-FY2025 were $1.14B; FY2026 adds equity investment impairment. Balance sheet goodwill risk is rising [S1, S2].
Bear Bullet 2: WBA Customer Risk Is Underappreciated WBA represents Cencora's largest single customer relationship, with supply agreement through 2029. WBA is closing thousands of stores, reporting operating losses in its U.S. pharmacy segment, and has been in financial distress for several years. If WBA's store closures are significant enough to reduce total pharmacy prescription volume (not merely shifting prescriptions to surviving WBA or other pharmacies), Cencora faces a structural revenue headwind. Furthermore, if WBA explores bankruptcy or a sale, contract renegotiation could reduce pricing or terms for Cencora. The top-2 customers represent ~42% of AR — this concentration is a vulnerability that the Street may be underpricing given current optimism around specialty expansion [S2].
Bear Bullet 3: Revenue Deceleration + Elevated Leverage = Multiple Compression Risk H1 FY2026 revenue growth of 4.7% is a sharp deceleration from FY2024's 12.1% and FY2025's 9.3%. Customer losses (oncology, grocery), GLP-1 growth normalization (from 43% to 23% to potentially mid-teens), and brand drug price deflation are all converging. Meanwhile, net debt has risen to ~$15-18B (from ~$4B in FY2023), interest expense has nearly doubled to ~$420M (FY2025) and will rise further in FY2026. If revenue growth settles at 4-6% vs. the double-digit rates of FY2024-FY2025, the Street may re-rate the stock to 12-13x earnings (lower for a decelerating compounder), implying downside to $210-$230 from current $265 [S5].
Conclusion
The current $265 stock price represents a significant sell-off from highs and embeds material pessimism about near-term GLP-1 and U.S. growth normalization. The bull case is better supported by the long-term specialty thesis and durable oligopolistic moat. The bear case has merit primarily around the M&A-induced leverage and WBA concentration risk. The most important near-term signposts are:
- FY2026 Q3 (April–June 2026) revenue and GP margin — will OneOncology contribution show in results?
- WBA pharmacy prescription volumes — any public disclosure of volume trends
- GLP-1 prescription data — IQVIA monthly data on semaglutide/tirzepatide prescriptions
Source Index
| ID | Source |
|---|---|
| S1 | Cencora FY2025 10-K, EDGAR |
| S2 | Cencora FY2024 10-K, EDGAR |
| S3 | Cencora Q2 FY2026 10-Q, EDGAR |
| S4 | other/consensus.md |
| S5 | Tavily search — analyst ratings, price targets, consensus estimates |
| S6 | Valuation estimates from consensus.md |
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.